Accueil   Diary - News   All news Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine

Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine

  • Tonghua Dongbao (THDB) will manufacture and supply insulin glargine and insulin lispro to Adocia worldwide, excluding China
  • These agreements expand the previously announced strategic alliance between both companies whereby THDB received licenses to develop and commercialize Adocia’s BioChaperone® Lispro and BioChaperone® Combo in China and other territories

 

ADOCIA (Euronext Paris: FR0011184241 – ADOC) and Tonghua Dongbao Pharmaceuticals (Shanghai Stock Exchange 600867) announced  an expansion of their strategic alliance with Tonghua Dongbao to manufacture and supply insulin lispro and insulin glargine APIs to Adocia worldwide, excluding China.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree